TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04646889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR882 Multiple Dose
Description: AR882 taken once daily for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR882 Multiple Dose
Description: AR882 taken once daily for 14 days
Study: NCT05286281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07265803
Description: PF-07265803 is a p38 inhibitor formulated for oral delivery.
Study: NCT05195970

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walnuts
Description: Participants consume 2 ounces of walnuts daily for 21 days
Study: NCT05485038

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor resection in awake patient
Description: Surgeon performs critical steps of tumor removal in awake patient and controls his/her motor functions by brain mapping and assessing of voluntary movements

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tumor resection in asleep patient
Description: Surgeon removes tumor in asleep patient and controls his/her motor functions by brain mapping
Study: NCT06679985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Solution for infusion
Study: NCT04819646

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Marine Lipid Oil Concentrate Formulation
Description: Marine Lipid Oil Concentrate softgels

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Supplement
Description: Dietary Supplement capsules
Study: NCT04840615

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LMB-100
Description: LMB-100 administered into lesion on days 1 and 4 during cycle 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipilimumab
Description: Administered intravenously once per cycle up to three 21-day cycles. Administration will occur during cycles 2,3,4.
Study: NCT05808205

Intervention type: DEVICE
Intervention: • ALIAXIN EV: Essential Volume • ALIAXIN FL: Lips • ALIAXIN SR: Shape & Restore • ALIAXIN GP: Global Performance • ALIAXIN LV: Lips Volume
Description: According the investigator judgment and IP' Instruction For Use (IFU), each subject can be treated in one or more of following face area:~* Temporal / frontal area~* Orbital / Malar area~* Perioral area~* Lips.
Study: NCT06679985

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Toripalimab
Description: Solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Solution for infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Solution for infusion
Study: NCT05987332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDE196
Description: Dosed orally, twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDE196
Description: Dosed orally, twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: Dosed orally, twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: Dosed orally, twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: IV administration every 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ipilimumab
Description: IV administration every 3 weeks for 4 Cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: IV administration every 3 Weeks for 4 Cycles, thereafter every 4 Weeks maintenance

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dacarbazine
Description: IV administration every 3 Weeks
Study: NCT06252649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI Regimen
Description: Combination of irinotecan, leucovorin, and 5-fluorouracil given intravenously Q2W.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFIRI Regimen
Description: Combination of irinotecan, leucovorin, and 5-fluorouracil given intravenously Q2W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotorasib
Description: Immediate-release solid dosage form administered PO.
Study: NCT06672809

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Exercise
Description: Participants in this group engage in aerobic exercise sessions that consist of warm-up, controlled-intensity walking, and a cool-down phase. This intervention serves as a comparative baseline, aiming to improve cardiovascular endurance without specifically targeting core stability. The aerobic routine is adjusted over time to increase exercise intensity, conducted three times per week for eight weeks, with each session lasting 50 minutes.
Study: NCT04379570

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Receive online educational information about ET medication

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Receive online educational information about ET medication

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Receive online educational information about ET medication

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Intervention
Description: Receive online educational information about ET medication

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text Message-based Navigation Intervention
Description: Receive text messages

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text Message-based Navigation Intervention
Description: Receive text messages

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: Receive motivational interviewing counseling sessions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: Receive motivational interviewing counseling sessions

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Attend usual care clinic visits

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT05020743

Intervention type: OTHER
Intervention: No intervention
Description: Not applicable for a Natural History Study

Intervention type: OTHER
Intervention: No intervention
Description: Not applicable for a Natural History Study
Study: NCT06676995

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Pulse Stimulation (TPS)
Description: Transcranial Pulse Stimulation (TPS) is a non invasive brain stimulation technology that applies repetitive single high-pressure ultrashort shockwave pulses within the ultrasound frequency range to stimulate the brain. Subjects will receive 12 TPS sessions conducted three times weekly, for about 40 to 50 minutes/day, over four consecutive weeks.
Study: NCT04758884

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine
Description: Visits by videoconference in months 0, 1, 2, 3, 4 and 6.
Study: NCT06252649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Administered IV Q2W.
Study: NCT04840615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: Infusion related reactions precaution: All participants will be premedicated with 25-50 mg Diphenhydramine by mouth (PO) or intravenous (IV) (or alternative antihistamine at adequate dose) 30-60 minutes (+ 30 minutes) prior to each LMB-100 administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine
Description: Infusion related reactions precaution: All participants will be premedicated with 20 mg Famotidine by mouth (PO) or intravenous (IV) (or alternative histamine H2- receptor antagonists (H2) blocker at adequate dose) 30-60 minutes (+ 30 minutes) prior to each LMB-100 administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Infusion related reactions precaution: All participants will be premedicated with 650 mg Acetaminophen by mouth (PO) or intravenous (IV) 30-60 minutes (+ 30 minutes) prior to each LMB-100 administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Additional infusion precaution at infusions of LMB-100 after Cycle 1 Day 1 (as appropriate): Dexamethasone 20 mg by mouth (PO), 6-12 hours prior to LMB-100 administration OR 10mg, intravenous (IV), 30-60 minutes prior to LMB-100 administration OR equivalent dose of another corticosteroid as clinically indicated.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: As feasible at screening, Cycle 1 Day 1 and 5, Cycle 2, 3, \& 4 Day 1, and Cycle 4 Day 21 (±7 days).
Study: NCT06252649

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab-awwb
Description: Administered IV Q2W.
Study: NCT05583071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafasitamab
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: IV
Study: NCT05447338

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Specific joint mobilization post muscle inhibition on C1
Description: Grasp the hand with the thumb or forefinger at the spinous process of C1. The contratoma hand is placed in forceps with the thumb and forefinger on the patient's temple, one on each side. Resisting with the hand on the temple, the therapist asks the patient to perform a 6-second isometric contraction of the cervical spine flexor muscles. The therapist then instructs the patient to relax the musculature and simultaneously performs posteroanterior pressure on the spinous process of C2 and passive extension of the head (with the hand on the temple). The maneuver is repeated until the therapist notices the release in the flexion-extension movement of the head.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Specific joint mobilization post muscle inhibition on C1
Description: Grasp the hand with the thumb or forefinger at the spinous process of C1. The contratoma hand is placed in forceps with the thumb and forefinger on the patient's temple, one on each side. Resisting with the hand on the temple, the therapist asks the patient to perform a 6-second isometric contraction of the cervical spine flexor muscles. The therapist then instructs the patient to relax the musculature and simultaneously performs posteroanterior pressure on the spinous process of C2 and passive extension of the head (with the hand on the temple). The maneuver is repeated until the therapist notices the release in the flexion-extension movement of the head.
Study: NCT04840615

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: FDG-PET
Description: At screening, at the end of cycles 2 \& 4 ± 7 days, Follow-Up Visit (4-6 weeks after end of treatment), and Long-Term Follow-Up (every 6-12 weeks).
Study: NCT04840615

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CT CAP
Description: At screening, at the end of cycles 2 \& 4 ± 7 days, Follow-Up Visit (4-6 weeks after end of treatment), and Long-Term Follow-Up (every 6-12 weeks).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI
Description: At screening, at the end of cycles 2 \& 4 ± 7 days, Follow-Up Visit (4-6 weeks after end of treatment), and Long-Term Follow-Up (every 6-12 weeks).
Study: NCT06679686

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Role Playing
Description: The group will analyse the instant cases given by the researchers using the role-play method.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital Storytelling
Description: The group will analyse the ethical analysis of the cases containing ethical problems written by themselves by using digital storytelling
Study: NCT04840615

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ECG
Description: At screening, Cycle 1 Day 1, Cycles 2, 3, \& 4 Day 1 and Follow-Up Visit (4-6 weeks after end of treatment).
Study: NCT05875441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxidectin Oral Product
Description: The required number of moxidectin 2 mg tablet over encapsulated capsules will be administered as a single dose with placebo capsules to match as required
Study: NCT04840615

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Echocardiogram
Description: At screening.
Study: NCT05875441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxidectin Oral Product
Description: The required number of moxidectin 2 mg tablet over encapsulated capsules will be administered as a single dose with placebo capsules to match as required

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxidectin Oral Product
Description: The required number of moxidectin 2 mg tablet over encapsulated capsules will be administered as a single dose.
Study: NCT06620406

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Synbiotic IVS-1
Description: A mixture of the prebiotic potato resistant starch (RS, Bobs Red Mill) and the probiotic IVS-1 (Bifidobacterium adolescentis).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Maltodextrin, a carbohydrate packaged similarly to the study intervention
Study: NCT05785741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DB-1310
Description: Administered I.V.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DB-1310
Description: Administered I.V.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DB-1310
Description: Administered I.V.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DB-1310
Description: Administered I.V.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DB-1310
Description: Administered I.V.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DB-1310
Description: Administered I.V.
Study: NCT05650216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy (nab-paclitaxel AUC=2 and carboplatin 80mg/m2)，Immunotherapy (camrelizumab 200mg)、Radiotherapy(primary lesion and adjacent lymph nodes 41.4Gy， distant lymph node 0.5Gy*4)
Description: 1. Neoadjuvant treatment period:~   Radiotherapy: Primary lesions and adjacent lymph nodes: The mode of involved field irradiation (IFI) is adopted, no preventive radiation is given. The total dose is 41.4Gy, 1.8Gy/23f. Distal lymph nodes ≥ 5cm away from the primary lesion: low-dose radiotherapy with a total dose of 4Gy, 0.5Gy/8f, Day1 to Day4, Day22 to Day25.~   Chemotherapy: Carboplatin(AUC=2), Nab-paclitaxel(80mg/m2), Day1/8/15/22/29. Immunotherapy: Camrelizumab(200mg, Day5, Day26).~2. Perioperative period:~   Undergo surgery within 4-6 weeks after neoadjuvant therapy~3. Adjuvant treatment period:~Camrelizumab: (200mg, Q3W)，continued for up to 1 years，until PD or intolerable toxicity.
Study: NCT04276792

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TCU Opioid-Treatment Linkage Model (O-TLM)
Description: The O-TLM is focused on best practices for improving screening, identifying and linking to MOUD providers, reducing stigma, and addressing other important factors that impact justice-involved individuals returning to their communities.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TCU Opioid-Treatment Linkage Model (O-TLM)
Description: The O-TLM is focused on best practices for improving screening, identifying and linking to MOUD providers, reducing stigma, and addressing other important factors that impact justice-involved individuals returning to their communities.
Study: NCT05328193

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthier Families, COVID Edition
Description: Families randomized to this arm with receive12-weekly health coaching calls virtually with their family with topics such as nutrition, physical activity, sleep, and media use.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teaching Kitchen Outreach
Description: Families receiving this intervention will recipe 11-weekly video recipes and groceries delivered to their door.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Teaching Kitchen Outreach
Description: Families receiving this intervention will recipe 11-weekly video recipes and groceries delivered to their door.
Study: NCT06173921

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: robotic system
Description: Implant placement will be navigated by robotic system based on a digital plan

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Static navigation system
Description: Implant placement will be navigated by static navigation system based on a digital plan
Study: NCT05875441

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 16 placebo capsules will be administered as a single dose.
Study: NCT05374590

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Efgartigimod IV or Efgartigimod PH20 SC
Description: Intravenous infusion of Efgartigimod or Subcutaneous injection of Efgartigimod PH20 SC
Study: NCT06149481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retifanlimab
Description: 500 mg infused via IV over 30 minutes every 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retifanlimab
Description: 500 mg infused via IV over 30 minutes every 28 days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Therapeutic CEA, Brachyury and MUC1 TriAdeno Vaccine Platform
Description: 5x10\^11 virus particles per 1 mL administered via subcutaneous injection in the upper arm and anterolateral upper thigh on Day 1 of Cycles 1, 2, 3 and every 3 cycles after that

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Therapeutic CEA, Brachyury and MUC1 TriAdeno Vaccine Platform
Description: 5x10\^11 virus particles per 1 mL administered via subcutaneous injection in the upper arm and anterolateral upper thigh on Day 1 of Cycles 1, 2, 3 and every 3 cycles after that

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-803
Description: 15 ug/kg administered via subcutaneous injection to the abdomen every 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-803
Description: 15 ug/kg administered via subcutaneous injection to the abdomen every 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SX-682
Description: 100 mg administered orally twice per day on days 6-26 of every cycle
Study: NCT06331364

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electronic clinical decision support tool (eCDST) diagnostic plan
Description: Participants will be followed for 30 days from enrollment to record clinical outcomes and any antimicrobials used. Analyses will compare clinical outcomes and antimicrobial use between the intervention arm and usual care.
Study: NCT06204848

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SVO-ID
Description: Combined scanning laser ophthalmoscope (SLO) and optical coherence tomography (OCT) for imaging of the eye
Study: NCT06619847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-993
Description: Tablets for oral administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HB/APAP
Description: Capsules for oral administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (matched to VX-993)
Description: Placebo matched to VX-993 for oral administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (matched to VX-993)
Description: Placebo matched to VX-993 for oral administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (matched to HB/APAP)
Description: Placebo matched to HB/APAP for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (matched to HB/APAP)
Description: Placebo matched to HB/APAP for oral administration.
Study: NCT05785741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DB-1310
Description: Administered I.V.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DB-1310
Description: Administered I.V.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DB-1310
Description: Administered I.V.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DB-1310
Description: Administered I.V.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DB-1310
Description: Administered I.V.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DB-1310
Description: Administered I.V.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DB-1310
Description: Administered I.V.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DB-1310
Description: Administered I.V.
Study: NCT06138015

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise and Time-Restricted Eating
Description: Moderate intensity circuit mixed endurance and resistance exercise programme two times per week for 55 minutes for 12 weeks and a time-restricted eating following 16:8 protocol for 12 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise only
Description: Moderate intensity circuit mixed endurance and resistance exercise programme two times per week for 55 minutes for 12 weeks only.
Study: NCT05785741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DB-1310
Description: Administered I.V.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DB-1310
Description: Administered I.V.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DB-1310
Description: Administered I.V.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DB-1310
Description: Administered I.V.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DB-1310
Description: Administered I.V.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DB-1310
Description: Administered I.V.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DB-1310
Description: Administered I.V.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DB-1310
Description: Administered I.V.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Administered I.V.